PDSB - PDS Biotech to license antigens from University of Georgia for universal flu vaccine

PDS Biotechnology (NASDAQ:PDSB) has licensed COBRA (Computationally Optimized Broadly Reactive Antigen) antigens from the University of Georgia for use in the development of PDS0202, its universal flu vaccine candidate. The antigens were selected following pre-clinical development work completed under a contract from the National Institute of Allergy and Infectious Diseases. PDS0202 use PDS' Versamune platform to induce the immune system to generate high levels of flu-specific neutralizing antibodies, CD4 helper and CD8 killer T-cells, as well as memory T-cells, to potentially provide long-term protection against multiple flu strains. Read about a recent development of a PDS candidate for HPV cancers.

For further details see:

PDS Biotech to license antigens from University of Georgia for universal flu vaccine